ProQR Therapeutics (PRQR) EBITDA (2013 - 2026)
ProQR Therapeutics (PRQR) posted quarterly EBITDA of -$15.5 million for Q1 2026, down 26.19% year-on-year from -$21.0 million in Q1 2025, and down 50.04% on a QoQ basis from -$10.4 million in Q4 2025.
ProQR Therapeutics (PRQR) EBITDA (2013 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported EBITDA for 14 consecutive years, with -$15.5 million the latest figure, recorded in Q1 2026.
- Quarterly EBITDA fell 26.19% year-over-year to -$15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.7 million (down 39.34% YoY) and the FY2025 annual result came in at -$49.4 million, down 42.58% from the prior year.
- EBITDA eased to -$15.5 million in Q1 2026 per PRQR's latest filing, from -$10.4 million in the prior quarter.
- Over the last five years, EBITDA for PRQR reached as high as -$4.1 million in Q2 2024 and fell as low as -$22.6 million in Q3 2022.
- A 5-year average of -$12.4 million and a median of -$11.5 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA soared 62.72% — and 2025, when it tumbled 240.25%.
- Year by year, EBITDA stood at -$14.2 million in 2022, then surged by 49.7% to -$7.1 million in 2023, then slumped by 60.83% to -$11.5 million in 2024, then gained by 9.76% to -$10.4 million in 2025, then plunged by 50.04% to -$15.5 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$15.5 million, -$10.4 million, and -$12.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -15.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.53 Mn |
| Dec 31, 2025 | -10.35 Mn |
| Sep 30, 2025 | -12.84 Mn |
| Jun 30, 2025 | -13.94 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Dec 31, 2024 | -11.47 Mn |
| Sep 30, 2024 | -9.92 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Mar 31, 2024 | -9.19 Mn |
| Dec 31, 2023 | -7.13 Mn |
| Sep 30, 2023 | -8.41 Mn |
| Jun 30, 2023 | -10.03 Mn |
| Mar 31, 2023 | -10.68 Mn |
| Dec 31, 2022 | -14.18 Mn |
| Sep 30, 2022 | -22.56 Mn |
| Jun 30, 2022 | -18.02 Mn |
| Mar 31, 2022 | -19.40 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -16.57 Mn |
| Jun 30, 2021 | -15.02 Mn |